Search

Your search keyword '"Yang Y. -W."' showing total 610 results
Start Over Author "Yang Y. -W."
610 results on '"Yang Y. -W."'

1. T0 Fan-out for Back-n White Neutron Facility at CSNS

Author

Ji, X. Y., Cao, P., Yu, T., Xie, L. K., Huang, X. R., An, Q., Bai, H. Y., Bao, J., Chen, Y. H., Cheng, P. J., Cui, Z. Q., Fan, R. R., Feng, C. Q., Gu, M. H., Han, Z. J., He, G. Z., He, Y. C., He, Y. F., Huang, H. X., Huang, W. L., Ji, X. L., Jiang, H. Y., Jiang, W., Jing, H. Y., Kang, L., Li, B., Li, L., Li, Q., Li, X., Li, Y., Liu, R., Liu, S. B., Liu, X. Y., Luan, G. Y., Ma, Y. L., Ning, C. J., Ren, J., Ruan, X. C., Song, Z. H., Sun, H., Sun, X. Y., Sun, Z. J., Tan, Z. X., Tang, J. Y., Tang, H. Q., Wang, P. C., Wang, Q., Wang, T. F., Wang, Y. F., Wang, Z. H., Wang, Z., Wen, J., Wen, Z. W., Wu, Q. B., Wu, X. G., Wu, X., Yang, Y. W., Yi, H., Yu, L., Yu, Y. J., Zhang, G. H., Zhang, L. Y., Zhang, J., Zhang, Q. M., Zhang, Q. W., Zhang, X. P., Zhao, Y. T., Zhong, Q. P., Zhou, L., Zhou, Z. Y., and Zhu, K. J.

Subjects
Physics - Instrumentation and Detectors, Electrical Engineering and Systems Science - Signal Processing
Abstract

the main physics goal for Back-n white neutron facility at China Spallation Neutron Source (CSNS) is to measure nuclear data. The energy of neutrons is one of the most important parameters for measuring nuclear data. Method of time of flight (TOF) is used to obtain the energy of neutrons. The time when proton bunches hit the thick tungsten target is considered as the start point of TOF. T0 signal, generated from the CSNS accelerator, represents this start time. Besides, the T0 signal is also used as the gate control signal that triggers the readout electronics. Obviously, the timing precision of T0 directly affects the measurement precision of TOF and controls the running or readout electronics. In this paper, the T0 fan-out for Back-n white neutron facility at CSNS is proposed. The T0 signal travelling from the CSNS accelerator is fanned out to the two underground experiment stations respectively over long cables. To guarantee the timing precision, T0 signal is conditioned with good signal edge. Furthermore, techniques of signal pre-emphasizing and equalizing are used to improve signal quality after T0 being transmitted over long cables with about 100 m length. Experiments show that the T0 fan-out works well, the T0 signal transmitted over 100 m remains a good time resolution with a standard deviation of 25 ps. It absolutely meets the required accuracy of the measurement of TOF., Comment: 3 pages, 6 figures, the 21st IEEE Real Time Conference

Published
2018

2. Electronics of Time-of-flight Measurement for Back-n at CSNS

Author

Yu, T., Cao, P., Ji, X. Y., Xie, L. K., Huang, X. R., An, Q., Bai, H. Y., Bao, J., Chen, Y. H., Cheng, P. J., Cui, Z. Q., Fan, R. R., Feng, C. Q., Gu, M. H., Han, Z. J., He, G. Z., He, Y. C., He, Y. F., Huang, H. X., Huang, W. L., Ji, X. L., Jiang, H. Y., Jiang, W., Jing, H. Y., Kang, L., Li, B., Li, L., Li, Q., Li, X., Li, Y., Liu, R., Liu, S. B., Liu, X. Y., Luan, G. Y., Ma, Y. L., Ning, C. J., Ren, J., Ruan, X. C., Song, Z. H., Sun, H., Sun, X. Y., Sun, Z. J., Tan, Z. X., Tang, J. Y., Tang, H. Q., Wang, P. C., Wang, Q., Wang, T. F., Wang, Y. F., Wang, Z. H., Wang, Z., Wen, J., Wen, Z. W., Wu, Q. B., Wu, X. G., Wu, X., Yang, Y. W., Yi, H., Yu, L., Yu, Y. J., Zhang, G. H., Zhang, L. Y., Zhang, J., Zhang, Q. M., Zhang, Q. W., Zhang, X. P., Zhao, Y. T., Zhong, Q. P., Zhou, L., Zhou, Z. Y., and Zhu, K. J.

Subjects
Physics - Instrumentation and Detectors, Electrical Engineering and Systems Science - Signal Processing
Abstract

Back-n is a white neutron experimental facility at China Spallation Neutron Source (CSNS). The time structure of the primary proton beam make it fully applicable to use TOF (time-of-flight) method for neutron energy measuring. We implement the electronics of TOF measurement on the general-purpose readout electronics designed for all of the seven detectors in Back-n. The electronics is based on PXIe (Peripheral Component Interconnect Express eXtensions for Instrumentation) platform, which is composed of FDM (Field Digitizer Modules), TCM (Trigger and Clock Module), and SCM (Signal Conditioning Module). T0 signal synchronous to the CSNS accelerator represents the neutron emission from the target. It is the start of time stamp. The trigger and clock module (TCM) receives, synchronizes and distributes the T0 signal to each FDM based on the PXIe backplane bus. Meantime, detector signals after being conditioned are fed into FDMs for waveform digitizing. First sample point of the signal is the stop of time stamp. According to the start, stop time stamp and the time of signal over threshold, the total TOF can be obtained. FPGA-based (Field Programmable Gate Array) TDC is implemented on TCM to accurately acquire the time interval between the asynchronous T0 signal and the global synchronous clock phase. There is also an FPGA-based TDC on FDM to accurately acquire the time interval between T0 arriving at FDM and the first sample point of the detector signal, the over threshold time of signal is obtained offline. This method for TOF measurement is efficient and not needed for additional modules. Test result shows the accuracy of TOF is sub-nanosecond and can meet the requirement for Back-n at CSNS., Comment: 4 pages, 13 figures, 21st IEEE Real Time Conference

Published
2018
Full Text
View/download PDF

5. Measurement of the neutron-induced total cross sections of natPb from 0.3 eV to 20 MeV on the Back-n at CSNS

Author

Xue, J, Feng, S, Chen, Y, Yi, H, Xiao, M, Cheng, P, Li, X, Liu, R, Yang, Y, Han, Z, Zhao, D, Wang, H, Li, B, Zhao, J, Tang, L, Luo, W, Zheng, B, Xue J. -M., Feng S., Chen Y. -H., Yi H., Xiao M., Cheng P. -J., Li X. -X., Liu R., Yang Y. -W., Han Z. -J., Zhao D. -J., Wang H. -Q., Li B. -Q., Zhao J. -R., Tang L. -X., Luo W., Zheng B., Xue, J, Feng, S, Chen, Y, Yi, H, Xiao, M, Cheng, P, Li, X, Liu, R, Yang, Y, Han, Z, Zhao, D, Wang, H, Li, B, Zhao, J, Tang, L, Luo, W, Zheng, B, Xue J. -M., Feng S., Chen Y. -H., Yi H., Xiao M., Cheng P. -J., Li X. -X., Liu R., Yang Y. -W., Han Z. -J., Zhao D. -J., Wang H. -Q., Li B. -Q., Zhao J. -R., Tang L. -X., Luo W., and Zheng B.

Abstract

The neutron-induced total cross sections of natural lead have been measured in a wide energy range (0.3 eV–20 MeV) on the back-streaming white neutron beamline (Back-n) at the China Spallation Neutron Source. Neutron energy was determined by the neutron total cross-section spectrometer using the time-of-flight technique. A fast multi-cell fission chamber was used as the neutron detector, and a 10-mm-thick high-purity natural lead sample was employed for the neutron transmission measurements. The on-beam background was determined using Co, In, Ag, and Cd filters. The excitation function of natPb(n, tot) reaction below 20 MeV was calculated using the TALYS-1.96 nuclear-reaction modeling program. The present results were compared with previous results, the evaluated data available in the five major evaluated nuclear data libraries (i.e., ENDF/B-VIII.0, JEFF-3.3, JENDL-5, CENDL-3.2, and BROND-3.1), and the theoretical calculation curve. Good agreement was found between the new results and those of previous experiments and with the theoretical curves in the corresponding region. This measurement obtained the neutron total cross section of natural lead with good accuracy over a wide energy range and added experimental data in the resonance energy range. This provides more reliable experimental data for nuclear engineering design and nuclear data evaluation of lead.

Published
2024

6. 78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1

Author

Bissonnette, R., primary, Pinter, A., additional, Ferris, L., additional, Gerdes, S., additional, Rich, P., additional, Vender, R., additional, Yang, Y.-W., additional, Miller, M., additional, Shen, Y.-K., additional, DeKlotz, C., additional, and Papp, K.A., additional

Published
2023
Full Text
View/download PDF

7. 77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study

Author

Pinter, A., primary, Eyerich, K., additional, Paller, A., additional, Kannan, A., additional, Strawn, D., additional, Horowitz, D., additional, Bhagat, S., additional, Richards, D., additional, Ruane, D., additional, McRae, B., additional, Yang, Y.-W., additional, Miller, M., additional, DeKlotz, C., additional, and Bissonnette, R., additional

Published
2023
Full Text
View/download PDF

8. 258 First-in-human results from a phase 1 single- and multiple-ascending dose study in healthy participants assessing the safety, pharmacokinetics, and pharmacodynamics of the interleukin-17A inhibitor JNJ-81241459

Author

Ling, I., primary, Leung, M., additional, Piantone, A., additional, Sinha, V., additional, Song, D., additional, Scott, B., additional, Pryor, M., additional, Verbruggen, K., additional, La, D., additional, Tikhonov, I., additional, Ceulemans, K., additional, Nischal, S., additional, Polak, M., additional, Eidam, P., additional, Goldberg, S., additional, Rao, R., additional, and Yang, Y.-W., additional

Published
2023
Full Text
View/download PDF

13. POS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS

Author

Coates, L., primary, Strober, B., additional, Yu, J., additional, Leibowitz, E., additional, Rowland, K., additional, Kollmeier, A., additional, Miller, M., additional, Wang, Y., additional, LI, S., additional, Chakravarty, S. D., additional, Chan, D., additional, Shawi, M., additional, Yang, Y. W., additional, Lebwohl, M., additional, and Rahman, P., additional

Published
2023
Full Text
View/download PDF

26. Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

Author

Reich, K., primary, Gordon, K.B., additional, Strober, B., additional, Langley, R.G., additional, Miller, M., additional, Yang, Y.‐W., additional, Shen, Y.‐K., additional, You, Y., additional, Zhu, Y., additional, Foley, P., additional, and Blauvelt, A., additional

Published
2022
Full Text
View/download PDF

27. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance

Author

Reich, K, Gordon, KB, Strober, B, Langley, RG, Miller, M, Yang, Y-W, Shen, Y-K, You, Y, Zhu, Y, Foley, P, Blauvelt, A, Reich, K, Gordon, KB, Strober, B, Langley, RG, Miller, M, Yang, Y-W, Shen, Y-K, You, Y, Zhu, Y, Foley, P, and Blauvelt, A

Abstract

BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disease that often leads to a diminished quality of life. Goals of treating patients with psoriasis have shifted with more focus on achieving near or complete clearance of the skin. Guselkumab, a fully human monoclonal antibody targeting interleukin-23, is effective in treating moderate-to-severe psoriasis. OBJECTIVE: To describe the baseline characteristics of patients with moderate-to-severe psoriasis achieving super-response (Psoriasis Area and Severity Index [PASI] 100 response at Weeks 20 and 28) after commencing guselkumab treatment. METHODS: Pooled data from VOYAGE 1 and VOYAGE 2 studies identified super-response; baseline demographic, disease and pharmacokinetic characteristics were compared with non-super-response. A stepwise logistic regression analysis identified which factors were potentially predictive of super-response status, with significance level of 0.1. RESULTS: A subset of patients randomized to guselkumab comprised this post hoc analysis (n = 664); 271 patients achieved super-response vs. 393 with non-super-response. Patient age at study entry and baseline body weight (≤90 kg vs. >90 kg), PASI, and Investigator's Global Assessment (IGA) score were significant predictors of super-response status, with odds ratios (95% confidence intervals) of 0.98 (0.967-0.993; P = 0.003), 1.42 (1.026-1.977; P = 0.034), 0.97 (0.955-0.993; P = 0.007) and 0.66 (0.433-0.997; P = 0.048), respectively. More patients with super-response achieved an early response: Week 2 PASI 75 (5.5% vs. 1.8%) and Week 8 PASI 100 (22.5% vs. 3.3%) vs. non-super-response. Median serum guselkumab concentrations through Week 28 were slightly greater in patients with super-response vs. non-super-response. CONCLUSION: Guselkumab was more likely to achieve early clinical responses (complete skin clearance) in younger patients, less obese patients and patients with less severe psoriasis.

Published
2022

30. AB0892 Targeted Safety Analyses of Guselkumab: Long-Term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis

Author

Mease, P. J., primary, Foley, P., additional, Reich, K., additional, Chakravarty, S. D., additional, Shawi, M., additional, Yang, Y. W., additional, Miller, M., additional, Kollmeier, A., additional, Xu, X. L., additional, Yu, J., additional, Wang, Y., additional, Sheng, S., additional, You, Y., additional, and Mcinnes, I., additional

Published
2022
Full Text
View/download PDF

31. AB1473 EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS

Author

Gordon, K., primary, Merola, J. F., additional, Foley, P., additional, Choi, O., additional, Chan, D., additional, Miller, M., additional, You, Y., additional, Shen, Y. K., additional, Yang, Y. W., additional, and Blauvelt, A., additional

Published
2022
Full Text
View/download PDF

32. AB0893 An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic Arthritis

Author

Merola, J. F., primary, Liu, Y. H., additional, Yang, Y. W., additional, Miller, M., additional, Shawi, M., additional, Chan, D., additional, Khattri, S., additional, Savage, L., additional, Boehncke, W. H., additional, and Han, C., additional

Published
2022
Full Text
View/download PDF

34. Clinical diagnostic performance of common laboratory indicators in primary glomerulonephritis.

Author

LI, X.-H., YANG, W.-Y., WANG, J., YANG, Y.-W., DAI, C.-M., ZHANG, B., and FENG, J.-F.

Abstract

OBJECTIVE: Immunoglobulin A nephropathy (IgAN) and membranous nephropathy (MN) are common types of primary glomerulonephritis (PGD). A lack of specific clinical features makes diagnosis difficult. Kidney function indicators have been used for their diagnosis. However, the diagnostic performance of these indicators is undetermined. The purpose of this paper is to evaluate their diagnostic potential. PATIENTS AND METHODS: 101 patients with PGD were enrolled, including 50 with MN and 51 with IgAN. The healthy controls included 110 volunteers. The indicators related to kidney function, including TP, ALB, Cre, CysC, eGFR, C1q, Ure, Anti-PLA2R, complement C3, and complement C4 in serum, ACR in urine, and antinuclear antibody profile, IgG staining, IgA staining, IgM staining, C3 staining and C1q staining in tissue samples were evaluated. RESULTS: Statistical differences were found in TP, ALB, Ure, CysC, eGFR, C1q, Anti-PLA2R, complement C3, complement C4 and ACR among the three groups of subjects. ROC analysis showed that Anti-PLA2R and ACR had the highest specificity for identifying IgAN and/or MN from the healthy controls, ACR had the highest sensitivity. The Sp and Se of IgA and IgG in tissue samples for the identification of IgAN and MN were both high. Both IgAN and MN were predicted by anti-PLA2R, especially MN. In tissue samples, MN patients were more likely to be IgG positive and IgAN patients were more likely to be IgA positive. CONCLUSIONS: IgAN and MN may be differentiated using serum Anti-PLA2R, tissue IgG, and tissue IgA. Cre is only useful in middle and late stages of GPDs, ACR is an exclusion marker, and CysC and C1q cannot be used to identify MN. [ABSTRACT FROM AUTHOR]

Published
2022

36. Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*

Author

Reich, K., primary, Gordon, K. B., additional, Strober, B. E., additional, Armstrong, A. W., additional, Miller, M., additional, Shen, Y. K., additional, You, Y., additional, Han, C., additional, Yang, Y. W., additional, Foley, P., additional, and Griffiths, C. E. M., additional

Published
2021
Full Text
View/download PDF

37. 1544P Soft tissue sarcoma (STS) incidences and clinical characteristics are significantly different between different geographic and ethnic populations

Author

Chen, T.W-W., primary, Chang, R.C-J., additional, Le Cesne, A., additional, Hsieh, Y-C., additional, Italiano, A., additional, Yang, Y-W., additional, Penel, N., additional, Lee, W-C., additional, Bompas, E., additional, Valentin, T., additional, Anract, P., additional, Firmin, N., additional, Duffaud, F., additional, Chan, K.A., additional, and Blay, J-Y., additional

Published
2021
Full Text
View/download PDF

47. AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR

Author

Gottlieb, A. B., primary, Merola, J. F., additional, Armstrong, A., additional, Langley, R., additional, Lebwohl, M., additional, Griffiths, C. E. M., additional, Shawi, M., additional, Yang, Y. W., additional, Hsia, E. C., additional, Kollmeier, A., additional, Xu, X. L., additional, Izutsu, M., additional, Ramachandran, P., additional, Sheng, S., additional, You, Y., additional, Miller, M., additional, Ritchlin, C. T., additional, McInnes, I., additional, and Rahman, P., additional

Published
2021
Full Text
View/download PDF

48. POS1031 LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR

Author

Mease, P. J., primary, Foley, P., additional, Reich, K., additional, Bagel, J., additional, Lebwohl, M., additional, Yang, Y. W., additional, Shawi, M., additional, Miller, M., additional, Kollmeier, A., additional, Hsia, E. C., additional, Xu, X. L., additional, Izutsu, M., additional, Ramachandran, P., additional, Sheng, S., additional, You, Y., additional, Helliwell, P., additional, and Boehncke, W. H., additional

Published
2021
Full Text
View/download PDF

49. The importance of analyzing the serum C3-epimer level for evaluating vitamin D storage in some special populations.

Author

CHEN, Y.-C., HE, Y.-Y., LI, Y.-M., WU, B.-T., YANG, Y.-W., and FENG, J.-F.

Abstract

OBJECTIVE: The serum 25-hydroxyvitamin D [25(OH)D] is recommended by various management agencies for evaluating the nutritional status of vitamin D (VitD). However, 25(OH)D cannot reflect the actual composition and activity of VitD in vivo. This study used UPLC-MS/MS to detect the levels of serum VitD metabolites in some special populations, so as to clarify its importance in accurately evaluating VitD storage in vivo. SUBJECTS AND METHODS: A total of 2029 subjects were enrolled, including 1204 cases in minor health (MH), 467 in the minor disease (MD), 119 in the adult health (AH) and 239 in adult disease (AD). Serum VitD2 and VitD3 levels were measured by UPLC-MS/MS. Serum C3-epi concentrations were also measured in 144 subjects by a spot check method. RESULTS: There were significant differences in the levels of VitD2, VitD3 and 25(OH)D among groups (all p <0.001). According to serum level of 25(OH)D, percentage of subjects with sufficient VitD in the MH, MD, AH and AD group were 65.4%, 52.7%, 29.4% and 20.9%, respectively. After converting VitD2 activity to AVitD3, subjects with sufficient VitD in MH, MD, AH and AD group accounted for 53.2%, 40.9%, 17.7% and 11.3%, respectively. C3-epi levels in the MH (z = 7.49, p <0.001), MD (z = 7.03, p <0.001) and AD group (z = 4.68, p <0.001) were higher than that in the AH group. CONCLUSIONS: Not only the serum 25(OH) D level, but also the simultaneous detection of VitD2 and VitD3 levels will overestimate the VitD storage in some subjects. Accurate evaluation of VitD storage in these individuals also requires detection of C3-epi levels. [ABSTRACT FROM AUTHOR]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results